Funding for this research was provided by:
H. Lundbeck A/S
Received: 21 June 2022
Accepted: 18 July 2022
First Online: 28 July 2022
: Approval for each study was provided by the independent ethics committee or institutional review board of the study site. The study was conducted in accordance with Good Clinical Practice guidelines, the principles of the Declaration of Helsinki, and all applicable regulatory requirements. Patients provided written informed consent prior to initiation of any study procedures.
: Not applicable.
: Dr. Cady was an employee of Lundbeck at the time of the study.Dr. Lipton has been a consultant, advisory board member, and/or has received honoraria from Lundbeck Seattle BioPharmaceuticals, Allergan/Abbvie, American Academy of Neurology, American Headache Society, Amgen, Biohaven Pharmaceuticals, electroCore Medical, Eli Lilly, eNeura Therapeutics, GlaxoSmithKline, Merck, Pernix, Pfizer, Teva Pharmaceuticals, and Vedanta. He holds stock or stock options in Biohaven Pharmaceuticals and Manistee.Dr. Buse is a part-time employee of Vector Psychometric Group, a company that has received funding from H. Lundbeck A/S for separate research, has received grant support from the US Food and Drug Administration and the National Headache Foundation, has received grant support and honoraria from Allergan, Amgen, Biohaven, Eli Lilly, Novartis, and Teva, and serves on the editorial board of Current Pain and Headache Reports.Dr. Josiassen, Ms. Lindsten, and Dr. Ettrup are employees of Lundbeck.